RAGWEED POLLEN ALLERGY TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Ragweed is an allergen for people allergic to ragweed. Ragweed pollen is made of tiny particles that float through the air and cause allergy symptoms in people who are allergic to ragweed. Of all ragweed allergy symptoms, cough, runny nose, and an itchy throat are the most common. Ragweed pollen is a powdery substance that consists of tiny particles, or grains. The grains of pollen help fertilize other ragweed plants. One ragweed plant can produce up to 1 billion pollen grains that can float through the air, and either produce seeds or end up in the nose, eyes or mouth, causing great discomfort if a person is allergic to it. Pollen can also collect on clothes, hair, and the skin. Like all pollen allergies, allergies to ragweed can lead to seasonal allergic rhinitis (hay fever), inflammation of the nasal passages. For people with a ragweed allergy, exposure to the plant by touch or through airborne particles can lead to them developing a ragweed rash. Other common ragweed allergy symptoms are: nasal congestion, runny nose with thin, water discharge, postnasal drip, sneezing, coughing, watery, itchy or irritated eyes, eye swelling– the “allergic shiner”, weakness or fatigue, hives on the skin. A person who has been exposed to ragweed pollen may notice itchy red streaks appearing on his skin 24 to 48 hours after exposure. The rash can be painful and may form into blisters. Ragweed rash can last anywhere from two to three weeks and will usually improve on its own. Ragweed pollen can cause asthma symptoms to flare up. When a person with asthma and ragweed allergy inhales ragweed pollen, it can cause the lungs and airways to become inflamed and swollen. People with allergic asthma will require treatment for its asthma symptoms, but they may also require treatment for its allergies.

Market Dynamics

Increasing launches of new products, and mergers and acquisitions by key market players is expected to drive the global ragweed pollen allergy treatment market growth. For instance, on April 19, 2021, ALK, a Denmark-based pharmaceutical company which specializes in the development and manufacture of allergy immunotherapy (AIT) products for the prevention and treatment of allergy, announced that the U.S. Food and Drug Administration (FDA) approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use for the treatment of short ragweed pollen-induced allergic rhinitis in persons ages five through 65. RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen.

Key features of the study:

• This report provides an in-depth analysis of the global ragweed pollen allergy treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ragweed pollen allergy treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG, and Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMerieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi, and Merck KGaA.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global ragweed pollen allergy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ragweed pollen allergy treatment market

Detailed Segmentation:

• Global Ragweed Pollen Allergy Treatment Market, By Drug Class:
  • Antihistamines
  • Decongestants
  • Nasal Corticosteroids
  • Others
• Global Ragweed Pollen Allergy Treatment Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Channel
• Global Ragweed Pollen Allergy Treatment Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Europe
    
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • ALK-Abello A/S
  • ASIT Biotech SA
  • Anergis SA
  • Biomay AG
  • Astellas Pharma Inc.
  • Thermo Fisher Scientific Inc
  • Siemens Healthcare Private Limited
  • Omega Diagnostics Group PLC
  • Stallergenes Greer
  • bioMerieux SA
  • Lincoln Diagnostics, Inc
  • HOB Biotech Group Corp Ltd
  • HYCOR Biomedical, Inc
  • Alcon
  • Hitachi Chemical Diagnostics, Inc
  • Quest Diagnostics Incorporated
  • Circassia
  • Immunomic Therapeutics, Inc
  • Novartis AG
  • Japan Tobacco Inc
  • GlaxoSmithKline plc
  • REGiMMUNE Co, Ltd
  • Sanofi
  • Merck KGaA.